Peter Mogayzel, director of the Cystic Fibrosis Center, discusses his presentation on the changing landscape of cystic fibrosis care, given during the 2023 North American Cystic Fibrosis Conference. The advent of highly effective CFTR modulators has transformed how practitioners approach care because patients are not as sick and have fewer clinic visits and hospitalizations. During this talk, Mogayzel explores the future of cystic fibrosis care.
Hello, I'm Peter Mogas, director of the Cystic Fibrosis Center at Johns Hopkins and I recently spoke at the North American cystic fibrosis conference about the changing landscape of cystic fibrosis care. The advent of highly effective CFTR modulators has really led to a transformation the way we approach care, people are sick less often, they come to clinic less often and are hospitalized less often. This has really led to a transformation the way we approach care we're thinking about the future. Should we continue to take the approach we've always taken of quarterly in person visits. Can virtual visits be interspersed with in person visits? Can we do home objective testing such as home starry or obtaining cultures at home to allow people not to have to travel to Johns Hopkins or other care centers to receive expert care. The CF Foundation has created a task force to look at these questions as well as how much daily care is required by people with cystic fibrosis to remain healthy. We hope to get information next year about best practices to try to understand the future of sister Psa's care. These changes also impact on the way we operate at Johns Hopkins and the way other centers around the country operate as well. How can we integrate our multidisciplinary care into virtual care and how we can support the mission of caring for patients leading cutting edge research and also supporting our patients in the community if we don't see them as frequently in clinic. It's an exciting time for people with cystic fibrosis and for us at Johns Hopkins, we look forward to the future. Thank you so much for listening.
Facebook
Twitter
YouTube
LinkedIn
Instagram
E-News
BROADCASTMED